ATIP

 

PAVM gained 95% in one month

 

FILL THE SHORT

ID	stock	broker	amount	AVG	PRICE TOTAL	date	time	Filled price	amount filled	volume	Total filled	total Stock	Total $	final price	Remark
104	PAVM	RH	$4.00	$24.52	$98.08	4/11/2024		$1.92	2,000.00	0	$3,840.00	2004	$3,938.08	$1.97
	-92% DOWN NET LOSS  -90.24$(DOWN)	12/06/2023 1:12 SPLIT PREVIOUS SHARE 51.9 NEW SHARE 3										$3,840.00

 

VTVT gained as of 8/5/2022 125% 3 months duration

 

MULN short today 8/4/2022

 

research daily price

ID	stock	DATE	BROKER	Avg	SHARE	market	percent	net loss or gain	open	high	Low	Float	avg volume	52High	52 Low	Remark	COMPANY
9	MULN	8/10/2022	RH	$0.84	110.00	$0.82	-2.88%	($2.66)	$0.80	$0.82	$0.78	65.69M	54.69	$15.90	$0.52	ONE WEEK+7.10 ONE MONTH-16.70 3 MONTH -26.97 ONE YEAR -92.96	EV AUTOMOTIVE
2	MULN	8/5/2022	RH	$0.84	110.00	$0.83	-0.92%	($0.85)	$0.84	$0.87	$0.83	31.52M	54.70M	$15.90	$0.52	ONE WEEK+7.10 ONE MONTH-16.70 3 MONTH -26.97 ONE YEAR -92.96

• Mullen Technologies (MULN) - Company CEO, David Michery, will interview on Benzinga's "Stock Market Movers With Money Mitch" YouTube show Thursday afternoon. Tune in to Benzinga's YouTube channel at 1:30 p.m. EDT to see and hear the interview.

ADAP news 8/4/2022

 9:41a ET 8/4/2022 - Benzinga

Adaptimmune Therapeutics: Q2 Earnings Insights

Mentioned:

ADAP

Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM.

Here's what investors need to know about the announcement.

Earnings

Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus an estimate of $-0.25.

Revenue was up $2.44 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.17 which was followed by a 1.3% increase in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:

QuarterQ1 2022Q4 2021Q3 2021Q2 2021

EPS Estimate-0.220.14-0.26-0.24

EPS Actual-0.05-0.04-0.30-0.24

Revenue Estimate3.29M96.45M1.37M1.36M

Revenue Actual3.58M1.42M1.20M3.10M

To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

ADAP news

 Adaptimmune Therapeutics Earlier Reported Q2 EPS $(0.05) Beats $(0.25) Estimate, Sales $5.54M Miss $6.00M Estimate

Mentioned:

ADAP

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.25) by 80 percent. This is a 79.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.54 million which missed the analyst consensus estimate of $6.00 million by 7.70 percent. This is a 78.93 percent increase over sales of $3.10 million the same period last year.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.